1485 completed, 454 recruiting, 420 terminated, 348 unknown. 3161 Phase 1, 1136 Phase 2.
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy Treating GI Cancer engineered immune cells - Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-11-02 |
| CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 1 | Not yet recruiting | City of Hope Medical Center | 36 | 2027-05-06 | 2026-09-25 |
| LMT503 First-in-human SAD, MAD, and FE Study LMT503, Placebo - Inflammatory Bowel Disease, Colitis, Ulcerative | Phase 1 | Not yet recruiting | Lmito Therapeutics Inc. | 72 | 2027-03-01 | 2026-09-01 |
| Xylitol Use for Decolonization of C. Difficile in Patients With IBD Xylitol, Placebo - Inflammatory Bowel Diseases, Clostridioides Difficile Infection | Phase 1 | Not yet recruiting | Brigham and Women's Hospital | 99 | 2027-03-01 | 2026-11-18 |
| A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). ST316 IV - Familial Adenomatous Polyposis (FAP) | Phase 1 | Not yet recruiting | Sapience Therapeutics | 40 | 2027-01-04 | 2026-08-12 |
| Outside the Cage (OTC) Robotic Esophagectomy OTC MIE Esophagectomy - Esophageal Cancer | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 31 | 2027-01-01 | 2026-03-18 |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis ATTO-1091, Placebo - Ulcerative Colitis (UC) | Phase 1 | Not yet recruiting | Attovia Therapeutics Inc | 96 | 2026-12-14 | 2026-09-15 |
| A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) DES-1357 - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Not yet recruiting | D. E. Shaw Research, LLC | 88 | 2026-12-03 | 2026-09-08 |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors SND002 Cell Injection - Colorectal Neoplasms, Stomach Neoplasms | Phase 1 | Not yet recruiting | Guizhou Sinorda Pharmaceutical Co., Ltd. | 78 | 2026-12-01 | 2026-11-04 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| A Study of LY4336619 in Adult Participants With Advanced Solid Tumors LY4336619, Sofetabart Mipitecan (Sofe-M) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 | Not yet recruiting | Eli Lilly and Company | 370 | 2026-12-01 | 2026-11-10 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-12-01 | 2026-11-16 |
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-11-30 | 2026-11-10 |
| A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies BMS-986548, Cetuximab - Advanced Solid Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 171 | 2026-11-30 | 2026-11-16 |
| A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours GSK5864399 - Solid Tumours | Phase 1 / Phase 2 | Not yet recruiting | GlaxoSmithKline | 155 | 2026-11-25 | 2026-11-18 |
Showing 20 of 3161. Sign in to see all of them.
Colorectal Neoplasms (1249) · Stomach Neoplasms (658) · Carcinoma, Non-Small-Cell Lung (496) · Colonic Neoplasms (431) · Esophageal Neoplasms (381) · Pancreatic Neoplasms (381) · Breast Neoplasms (370) · Ovarian Neoplasms (314) · Rectal Neoplasms (312) · Neoplasms (278) · Neoplasm Metastasis (258) · Lung Neoplasms (240) · Melanoma (235) · Squamous Cell Carcinoma of Head and Neck (210) · Colitis, Ulcerative (185)
Digestive System Diseases (3144) · Digestive System Neoplasms (2334) · Neoplasms by Site (2323) · Gastrointestinal Neoplasms (2217) · Intestinal Diseases (2193) · Neoplasms (2127) · Colonic Diseases (1715) · Intestinal Neoplasms (1601) · Rectal Diseases (1497) · Neoplasms by Histologic Type (873) · Stomach Diseases (726) · Neoplasms, Glandular and Epithelial (700) · Respiratory Tract Diseases (681) · Lung Diseases (668)
Fluorouracil (185) · Oxaliplatin (180) · pembrolizumab (166) · Capecitabine (152) · Irinotecan (141) · Leucovorin (133) · Cetuximab (132) · Bevacizumab (124) · Cisplatin (95) · Paclitaxel (87) · Nivolumab (82) · Radiotherapy (78) · Cyclophosphamide (69) · Carboplatin (65) · Gemcitabine (60)
National Cancer Institute (NCI) (124) · M.D. Anderson Cancer Center (47) · Pfizer (47) · GlaxoSmithKline (45) · AstraZeneca (38) · Novartis Pharmaceuticals (38) · Memorial Sloan Kettering Cancer Center (31) · Mayo Clinic (29) · Eli Lilly and Company (27) · Bristol-Myers Squibb (25) · City of Hope Medical Center (22) · National Institute of Allergy and Infectious Diseases (NIAID) (21) · Incyte Corporation (20) · Merck Sharp & Dohme LLC (20) · Roswell Park Cancer Institute (20)
United States (1708) · China (463) · South Korea (262) · Spain (237) · United Kingdom (220) · Australia (215) · Canada (209) · France (204) · Germany (162) · Japan (158) · Netherlands (136) · Belgium (129) · Italy (126) · Taiwan (95) · Denmark (65)
Amy Lightner, MD (7)
PMID 40056080, PMID 17560413, PMID 18590344, PMID 18590345, PMID 22607579, PMID 26808342, PMID 27490698, PMID 28735965, PMID 30277655, PMID 31527168, PMID 34017343, PMID 35219300, PMID 35362047, PMID 35537408, PMID 36897458, PMID 36977960, PMID 37082579, PMID 37496366, PMID 37590355, PMID 37788341, PMID 37917289, PMID 37934000, PMID 38267790, PMID 38580386, PMID 39462179, PMID 40443562, PMID 41044356, PMID 42201333, PMID 42580817, PMID 10235156, PMID 10496568, PMID 10628373, PMID 10655252, PMID 10811496, PMID 11127145, PMID 11573045, PMID 11705489, PMID 11743810, PMID 11870157, PMID 11919232, PMID 11919233, PMID 12049861, PMID 12196376, PMID 12393999, PMID 12454110, PMID 12528778, PMID 12576903, PMID 12607634, PMID 12663720, PMID 12680184
2023 (47), 2016 (28), 2025 (27), 2017 (24), 2019 (24), 2015 (19), 2018 (17), P30CA033572 (13), 2009 (11), 2014 (10), 2008 (9), P30CA016672 (9), UM1CA186690 (7), P30CA015083 (6), P30CA016056 (6)